focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFST.L Regulatory News (FST)

  • There is currently no data for FST

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Start of digital plaster pilot

1 Nov 2012 07:00

RNS Number : 0301Q
Toumaz Limited
01 November 2012
 



1 November 2012

 

Toumaz Limited

 

Major hospital pilot deployment of Toumaz's wireless plaster to monitor vital signs underway

 

Toumaz Limited (AIM: TMZ, 'Toumaz', or the 'Group'), a pioneer in low cost, ultra-low power wireless technology, has started to pilot its digital vital signs plaster, SensiumVitals, in a major US hospital. 

 

The SensiumVitals monitor is a disposable, ultra-thin plaster which continuously monitors the patient's heart rate, respiratory rate and temperature whilst in hospital. This significantly increases patient surveillance compared to current practice, which involves manual measurement of vital signs every six to eight hours.

 

The device, which also has an alert capability, enables patients to be fully mobile whilst being monitored, so helping to promote patient morale and recovery. SensiumVitals is targeted at the general wards of hospitals which account for the vast majority of hospital beds, unlike traditional, bulky, wired monitoring products which are usually only found in hospital intensive care units.

 

SensiumVitals also provides hospitals with significant cost-savings as continuous monitoring can reduce the number of patients who have to be admitted or readmitted to costly intensive care, as any deterioration in condition can be alerted and dealt with immediately.

In the US alone, wireless vital signs monitoring devices are forecast to reduce healthcare costs by around $200 billion over the next 25 years. (Center for Technology and Aging Report, May 2010).

The pilot is being carried out at St. John's Health Centre in Santa Monica, California, by Toumaz US, the Group's US joint venture with Dr Patrick Soon-Shiong's company, NantWorks.

 

Anthony Sethill, CEO of Toumaz, commented:

 

"This pilot is a major milestone for the Group as we start to commercialise our low cost, ultra-low power wireless technologies for use in the medical markets.

 

 "This disruptive wireless monitoring technology is the world's first FDA cleared and fully disposable vital signs monitoring solution for general use in hospitals. SensiumVitals represents a breakthrough in how patient care is delivered, setting a new, cost effective standard for hospitals and also benefitting patients' recovery.

 

"Early feedback from patients and hospital staff has been very positive with the device detecting deterioration in patients' conditions instantaneously, enabling intervention much sooner than normal."

 

Michael Trevino, CTO of NantHealth, a NantWorks company, commented:

 

"At NantWorks we believe continuous patient monitoring in the hospital will one day be standard practice and this will be enabled by foundational technology like SensiumVitals, delivered by Toumaz US. Continuously streamed patient data automatically flowing into hospital information systems will drive the right care at the right time and in the right place."

  

Enquiries:

 

Toumaz

+44 (0)1235 438950

Anthony Sethill, Chief Executive Officer

Peel Hunt LLP (Nominated Adviser and Broker)

+44 (0)20 7418 8900

Richard Kauffer/Daniel Harris

College Hill (Financial PR)

+44 (0)20 7457 2020

Adrian Duffield/Rozi Morris

 

About SensiumVitals

 

The SensiumVitals digital plaster is a fully disposable device, with smart sensor interface and transceiver, aimed at the general wards of hospitals. The device continuously monitors patients' vital signs (heart-rate, respiration rate & temperature) and wirelessly communicates this data to doctors and nurses via the hospital's IT system.

 

Currently, the majority of patients in hospital have measurements of vital signs taken manually at six to eight hour intervals. This relatively infrequent monitoring means that deterioration in patient conditions may go unnoticed, leading to further treatment or re-admittance to intensive care units.

 

The SensiumVitals monitor is a disposable ultra-thin plaster that is attached to patients under their clothing. The device enables the patient to be completely ambulatory and still be monitored.

 

Hospital staff can set up alerts that can be sent to pagers/handheld devices to warn them of patient deterioration. This enables caregivers to prioritise patients based on their condition. SensiumVitals has a battery life of five days, covering the average length of a general ward stay in the hospital. At the end of a patient's stay the entire device can be disposed of.

 

Key benefits include:

·; Enables early detection of deterioration - patients at risk can be treated sooner / improves patient safety

·; Lightweight unobtrusive wireless plaster is comfortable to wear and enables patients to be ambulatory - improves patient recovery

·; Plasters can be disposed of after use - no risk of infection transmission from one patient to another

·; Integrates well with existing clinical workflows and will be useful for generating patient early warning scores

 

About Toumaz - (www.toumazltd.com)

 

Toumaz is a pioneer in low cost, ultra-low power wireless technologies for a wide range of markets including medical monitoring and internet connected consumer devices. The recent acquisition of Frontier Silicon brings operational scale and expertise together with a leadership position in digital and networked audio markets.

 

The Group combines its strong IP and technology base with the commercial scale of Frontier to exploit two key wireless technology sectors:

·; Professional healthcare solutions

·; Consumer semiconductors in digital audio and sport & health markets

 

Toumaz's ultra-low power sensor platform, Sensium™, targets the professional healthcare market and is a leader in real-time wireless monitoring of the body's vital signs with the potential to transform medical monitoring and reduce the cost of healthcare. SensiumVitals is the Group's first product in this field. For healthcare professionals, this creates new opportunities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for personalised healthcare.

 

Toumaz plans to transfer its Sensium™ technology to the consumer sports and health market, where its advanced measurement algorithms and low energy solutions give it a competitive advantage.

 

Toumaz is also using its expertise to design devices for wireless connectivity and internet-connected The acquisition of Frontier Silicon has enhanced the Group's technology portfolio in Network Audio and elevates Toumaz to a market leadership position in this and the digital radio markets. The Group now supplies multimedia/FM/DAB chips and modules to all major audio brands.

 

Toumaz is an AIM listed company (AIM: TMZ) with development centres in Oxford and Cambridge in the UK and in Hong Kong and in Shenzhen in the People's Republic of China.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCMBBRTMBTJBIT
Date   Source Headline
20th Feb 201210:16 amRNSHolding(s) in Company
16th Feb 20127:00 amRNSCompletion of placing
13th Feb 20127:00 amRNSPlacing raises £11.2m
13th Feb 20127:00 amRNSTrading update
3rd Jan 20127:00 amRNSSubsidiary established with Imagination Technologi
24th Oct 20117:00 amRNSTelran distribution clearance
21st Sep 20117:00 amRNSHalf year results
9th Aug 20114:52 pmRNSNotice of Results
29th Jul 20117:00 amRNSHalf year trading update
11th Jul 20117:00 amRNSFDA approval for Sensium
11th Jul 20117:00 amRNSJV established with CCE
5th May 20115:24 pmRNSResult of AGM
29th Mar 20117:00 amRNSFull year results
16th Mar 20113:16 pmRNSNotice of Results
16th Mar 20113:05 pmRNSHolding(s) in Company
3rd Mar 20114:34 pmRNSIssue of Equity
2nd Mar 20118:14 amRNS£1.8m Raised
10th Feb 20117:41 amRNSStrategic Investment
1st Feb 20117:00 amRNSTELRAN Launch
1st Feb 20117:00 amRNSYear End Trading Update
30th Nov 20107:00 amRNSXENIF processor in production
15th Sep 20107:00 amRNSInterim Results
24th Aug 20109:33 amRNSIssue of Equity
11th Aug 201011:52 amRNSNotice of Results
27th Jul 20107:00 amRNSLicense agreement
15th Jul 201010:19 amRNSIssue of Equity and Exercise of Options
30th Jun 20107:00 amRNSTrading Update
16th Jun 20108:49 amRNSAnnual Financial Report
26th May 20109:07 amRNSChange of Name
10th May 20102:52 pmRNSResult of AGM
30th Mar 20107:00 amRNSFinal Results
12th Mar 20109:00 amRNSQuanta takes strategic stake
11th Mar 20104:27 pmRNSDirector dealings
10th Mar 201011:26 amRNSNotice of Results
23rd Feb 20107:00 amRNSClinical Trial Update
1st Feb 20102:02 pmRNSExercise of Options - replacement
29th Jan 201012:33 pmRNSExercise of Options
22nd Dec 200911:19 amRNSHolding(s) in Company
21st Dec 20097:00 amRNSHolding(s) in Company
17th Dec 20093:10 pmPRNResult of EGM
14th Dec 20093:34 pmPRNDirector/PDMR Shareholding
1st Dec 20097:00 amPRNProposed Placing and Update
9th Nov 20091:20 pmRNSNational Microelectronics Institute Award
2nd Nov 20097:00 amPRNSensium Digital Plaster European Trial
28th Sep 20097:00 amPRNHalf-yearly Report
22nd Sep 200912:16 pmRNSHolding(s) in Company
11th Sep 20097:00 amRNSCorrection re holding in company
10th Sep 20097:00 amRNSHolding(s) in Company
7th Aug 200912:01 pmRNSHolding(s) in Company
22nd Jul 200911:21 amPRNResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.